Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan-Sarbecoviruses

Abstract

The ongoing emergence of new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) underscores the urgent need for developing antivirals targeting both SARS-CoV-2 variants and related sarbecoviruses. To this end, we designed novel trispecific antibodies, Tri-1 and Tri-2, engineered by fusing the single-chain variable fragments (scFvs) of a potent antibody (PW5-570) to the Fc region of “Knob-into-Hole” bispecific antibodies (bsAbs) composed of two distinct broad antibodies (PW5-5 and PW5-535). Compared with the parental antibodies, Tri-1 and Tri-2 displayed enhanced binding affinities to the receptor-binding domains of SARS-CoV, SARS-CoV-2 wild type, and Omicron XBB.1.16, with each arm contributed to the overall enhancement. Furthermore, pseudovirus neutralization assays revealed that Tri-1 and Tri-2 effectively neutralized all tested SARS-CoV, SARS-CoV-2 variants, and related sarbecoviruses (Pangolin-GD, RaTG13, WIV1, and SHC014), demonstrating potency and breadth superior to any single parental antibody. Consistently, Tri-1 and Tri-2 were found to effectively neutralize authentic SARS-CoV and SARS-CoV-2 variants with IC₅₀ values comparable to or better than those of parental antibodies. Taken together, this study highlights the potential effectiveness of Tri-1 and Tri-2 as novel formats for harnessing cross-neutralizing antibodies in the development of multivalent agents to combat both current and future SARS-like coronaviruses.

Keywords

coronavirus / sarbecovirus / SARS-CoV-2 / bispecific antibody / trispecific antibody / broadly neutralizing antibody

References

[1] D. Focosi, S. McConnell, A. Casadevall, et al., “Monoclonal Antibody Therapies Against SARS-CoV-2,” The Lancet Infectious Diseases 22 (2022): e311-e326.

[2] L. Zhou, C. Mo, Y. Yang, et al., “Characterization and Application of a Series of Monoclonal Antibodies Against SARS-CoV-2 Nucleocapsid Protein,” Journal of Medical Virology 95 (2023): e28225.

[3] K. Westendorf, S. Zentelis, L. Wang, et al., “LY-CoV1404 (Bebtelovimab) Potently Neutralizes SARS-CoV-2 Variants,” Cell Reports 39 (2022): 110812.

[4] C. G. Rappazzo, L. V. Tse, C. I. Kaku, et al., “Broad and Potent Activity Against SARS-Like Viruses by an Engineered Human Monoclonal Antibody,” Science 371 (2021): 823-829.

[5] R. Copin, A. Baum, E. Wloga, et al., “The Monoclonal Antibody Combination REGEN-COV Protects Against SARS-CoV-2 Mutational Escape in Preclinical and Human Studies,” Cell 184 (2021): 3949-3961.e11.

[6] B. Perez-Masson, Y. Quintana-Perez, Y. Tundidor, et al., “Studying SARS-CoV-2 Interactions Using Phage-Displayed Receptor Binding Domain as a Model Protein,” Scientific Reports 14 (2024): 712.

[7] A. J. Greaney, T. N. Starr, C. O. Barnes, et al., “Mapping Mutations to the SARS-CoV-2 RBD That Escape Binding by Different Classes of Antibodies,” Nature Communications 12 (2021): 4196.

[8] C. O. Barnes, C. A. Jette, M. E. Abernathy, et al., “SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic Strategies,” Nature 588 (2020): 682-687.

[9] J. Lan, J. Ge, J. Yu, et al., “Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor,” Nature 581 (2020): 215-220.

[10] C. B. Jackson, M. Farzan, B. Chen, et al., “Mechanisms of SARS-CoV-2 Entry Into Cells,” Nature Reviews Molecular Cell Biology 23 (2022): 3-20.

[11] X. Chi, R. Yan, J. Zhang, et al., “A Neutralizing human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2,” Science 369 (2020): 650-655.

[12] L. Liu, P. Wang, M. S. Nair, et al., “Potent Neutralizing Antibodies Against Multiple Epitopes on SARS-CoV-2 Spike,” Nature 584 (2020): 450-456.

[13] Y. Liu, X. Zhao, J. Shi, et al., “Lineage-Specific Pathogenicity, Immune Evasion, and Virological Features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3,” Nature Communications 15 (2024): 8728.

[14] D. Planas, I. Staropoli, V. Michel, et al., “Distinct Evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineages Combining Increased Fitness and Antibody Evasion,” Nature Communications 15 (2024): 2254.

[15] K. Khan, G. Lustig, C. Romer, et al., “Evolution and Neutralization Escape of the SARS-CoV-2 BA.2.86 Subvariant,” Nature Communications 14 (2023): 8078.

[16] Q. Wang, S. Iketani, Z. Li, et al., “Alarming Antibody Evasion Properties of Rising SARS-CoV-2 BQ and XBB Subvariants,” Cell 186 (2023): 279-286. e8.

[17] M. R. Chang, L. Tomasovic, N. A. Kuzmina, et al., “IgG-Like Bispecific Antibodies With Potent and Synergistic Neutralization Against Circulating SARS-CoV-2 Variants of Concern,” Nature Communications 13 (2022): 5814.

[18] Y. Huang, J. Yu, A. Lanzi, et al., “Engineered Bispecific Antibodies With Exquisite HIV-1-Neutralizing Activity,” Cell 165 (2016): 1621-1631.

[19] R. De Gasparo, M. Pedotti, L. Simonelli, et al., “Bispecific IgG Neutralizes SARS-CoV-2 Variants and Prevents Escape in Mice,” Nature 593 (2021): 424-428.

[20] S. Bournazos, A. Gazumyan, M. S. Seaman, et al., “Bispecific Anti-HIV-1 Antibodies With Enhanced Breadth and Potency,” Cell 165 (2016): 1609-1620.

[21] J. Wang, M. Bardelli, D. A. Espinosa, et al., “A Human Bi-Specific Antibody Against Zika Virus With High Therapeutic Potential,” Cell 171 (2017): 229-241. e15.

[22] A. Baum, B. O. Fulton, E. Wloga, et al., “Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies,” Science 369 (2020): 1014-1018.

[23] C. Klein, U. Brinkmann, J. M. Reichert, et al., “The Present and Future of Bispecific Antibodies for Cancer Therapy,” Nature Reviews Drug Discovery 23 (2024): 301-319.

[24] N. van de Donk and S. Zweegman, “T-Cell-Engaging Bispecific Antibodies in Cancer,” Lancet 402 (2023): 142-158.

[25] S. X. Wang, S. B. Abramson, M. Attur, et al., “Safety, Tolerability, and Pharmacodynamics of an Anti-Interleukin-1alpha/Beta Dual Variable Domain Immunoglobulin in Patients With Osteoarthritis of the Knee: A Randomized Phase 1 Study,” Osteoarthritis and Cartilage 25 (2017): 1952-1961.

[26] Q. Zhao, “Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date,” Biodrugs 34 (2020): 111-119.

[27] M. Asokan, R. S. Rudicell, M. Louder, et al., “Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization,” Journal of Virology 89 (2015): 12501-12512.

[28] K. Wagner, M. J. Kwakkenbos, Y. B. Claassen, et al., “Bispecific Antibody Generated With Sortase and Click Chemistry Has Broad Antiinfluenza Virus Activity,” PNAS 111 (2014): 16820-16825.

[29] M. Zanin, Z. Y. Keck, G. J. Rainey, et al., “An Anti-H5N1 Influenza Virus FcDART Antibody Is a Highly Efficacious Therapeutic Agent and Prophylactic Against H5N1 Influenza Virus Infection,” Journal of Virology 89 (2015): 4549-4561.

[30] W. Tan, Y. Meng, H. Li, et al., “A Bispecific Antibody Against Two Different Epitopes on Hepatitis B Surface Antigen Has Potent Hepatitis B Virus Neutralizing Activity,” MAbs 5 (2013): 946-955.

[31] X. Shi, Y. Deng, H. Wang, et al., “A Bispecific Antibody Effectively Neutralizes all Four Serotypes of Dengue Virus by Simultaneous Blocking Virus Attachment and Fusion,” MAbs 8 (2016): 574-584.

[32] J. C. Frei, E. K. Nyakatura, S. E. Zak, et al., “Bispecific Antibody Affords Complete Post-Exposure Protection of Mice From Both Ebola (Zaire) and Sudan Viruses,” Scientific Reports 6 (2016): 19193.

[33] J. Hansen, A. Baum, K. E. Pascal, et al., “Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail,” Science 369 (2020): 1010-1014.

[34] Z. Ku, X. Xie, J. Lin, et al., “Engineering SARS-CoV-2 Specific Cocktail Antibodies Into a Bispecific Format Improves Neutralizing Potency and Breadth,” Nature Communications 13 (2022): 5552.

[35] D. Pinto, Y. J. Park, M. Beltramello, et al., “Cross-neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody,” Nature 583 (2020): 290-295.

[36] Y. Cao, F. Jian, Z. Zhang, et al., “Rational Identification of Potent and Broad Sarbecovirus-Neutralizing Antibody Cocktails From SARS Convalescents,” Cell Reports 41 (2022): 111845.

[37] X. Zhao, T. Qiu, X. Huang, et al., “Potent and Broadly Neutralizing Antibodies Against Sarbecoviruses Induced by Sequential COVID-19 Vaccination,” Cell Discovery 10 (2024): 14.

[38] P. V. Markov, M. Ghafari, M. Beer, et al., “The Evolution of SARS-CoV-2,” Nature Reviews Microbiology 21 (2023): 361-379.

[39] C. Roemer, D. J. Sheward, R. Hisner, et al., “SARS-CoV-2 Evolution in the Omicron Era,” Nature Microbiology 8 (2023): 1952-1959.

[40] Y. Cao, J. Wang, F. Jian, et al., “Omicron Escapes the Majority of Existing SARS-CoV-2 Neutralizing Antibodies,” Nature 602 (2022): 657-663.

[41] D. R. Burton and E. J. Topol, “Variant-Proof Vaccines—Invest Now for the Next Pandemic,” Nature 590 (2021): 386-388.

[42] P. Zhou, X. L. Yang, X. G. Wang, et al., “A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin,” Nature 579 (2020): 270-273.

[43] E. K. Nyakatura, A. Y. Soare, and J. R. Lai, “Bispecific Antibodies for Viral Immunotherapy,” Human Vaccines & Immunotherapeutics 13 (2017): 836-842.

[44] A. F. Labrijn, M. L. Janmaat, J. M. Reichert, et al., “Bispecific Antibodies: A Mechanistic Review of the Pipeline,” Nature Reviews Drug Discovery 18 (2019): 585-608.

[45] X. Wu, J. Guo, M. Niu, et al., “Tandem Bispecific Neutralizing Antibody Eliminates HIV-1 Infection in Humanized Mice,” Journal of Clinical Investigation 128 (2018): 2239-2251.

[46] Z. Z. Gao, J. Y. Jiao, Y. Q. Zhou, et al., “A Novel Monospecific Tetravalent IgG1-(scFv)(2) Version Shown Enhanced Neutralizing and Fc-Mediated Effector Functions Against SARS-CoV-2,” BioTechniques 13 (2023): 283.

[47] Y. Liu, Z. Wang, X. Zhuang, et al., “Inactivated Vaccine-Elicited Potent Antibodies Can Broadly Neutralize SARS-CoV-2 Circulating Variants,” Nature Communications 14 (2023): 2179.

[48] H. Sun, T. Deng, Y. Zhang, et al., “Two Antibodies Show Broad, Synergistic Neutralization Against SARS-CoV-2 Variants by Inducing Conformational Change Within the RBD,” Protein Cell 15 (2024): 121-134.

[49] N. Y. Pang, A. S. Pang, V. T. Chow, et al., “Understanding Neutralising Antibodies Against SARS-CoV-2 and Their Implications in Clinical Practice,” Military Medical Research 8 (2021): 47.

[50] L. Niu, K. N. Wittrock, G. C. Clabaugh, et al., “A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain,” Frontiers in Immunology 12 (2021): 647934.

[51] X. Wang, X. Zhao, Y. Cui, et al., “Neutralization of Distinct Omicron Sublineages by Longitudinal Vaccination Sera,” Journal of Medical Virology 94 (2022): 5090-5092.

[52] H. Chu, Y. Hou, D. Yang, et al., “Coronaviruses Exploit a Host Cysteine-Aspartic Protease for Replication,” Nature 609 (2022): 785-792.

[53] J. F. Chan, X. Huang, B. Hu, et al., “Altered Host Protease Determinants for SARS-CoV-2 Omicron,” Science Advances 9 (2023): eadd3867.

[54] H. Shuai, J. F. Chan, B. Hu, et al., “Attenuated Replication and Pathogenicity of SARS-CoV-2 B.1.1.529 Omicron,” Nature 603 (2022): 693-699.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.